The FTC's rationale; Who owns what; Treatment IDE proposal online

WASHINGTON - A number of observers were taken aback by last week's Federal Trade Commission decision to make approval of the merger of Ciba-Geigy and Sandoz into Novartis contingent on the companies' agreement to make certain gene therapy technologies widely available. Their worry was that the decision would pave the way for the FTC to require merging companies to divest early-stage technologies, as opposed to marketed products. However, the FTC told BioCentury that it is

Read the full 752 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE